Isomorphic Labs has secured $600 million in its first external funding round to develop its AI drug design engine and advance therapeutic programs into clinical trials. The round is led by Thrive Capital, with participation from GV and Alphabet. Based in London and Lausanne, Switzerland, the company uses AI models like AlphaFold 3 to accelerate drug discovery across areas such as oncology and immunology through collaborations with Eli Lilly and Novartis.
Isomorphic Labs has secured $600 million in its first external funding round, led by Thrive Capital, with participation from GV and follow-on capital from Alphabet. This investment will support the company’s efforts to advance its next-generation AI drug design engine and expand its therapeutic pipeline into clinical development. The funding underscores the growing recognition of AI’s potential to revolutionize drug discovery and accelerate the delivery of new treatments.
The company plans to use the funds to deepen its frontier AI research, enhance its unified AI drug design engine, and scale its portfolio of drug candidates across multiple therapeutic areas. Isomorphic Labs has already established collaborations with leading pharmaceutical companies, including Eli Lilly and Novartis, while also advancing internal programs focused on oncology and immunology.
The investment reflects confidence in Isomorphic Labs’ ability to redefine AI-powered drug discovery. Thrive Capital’s Joshua Kushner highlighted the company’s unique position at the intersection of AI and life sciences. At the same time, GV’s Krishna Yeshwant emphasized the potential for Isomorphic Labs to unlock new possibilities in drug design through its interdisciplinary approach.
Mission and Vision: Transforming Drug Discovery with AI
Isomorphic Labs aims to transform drug discovery by leveraging advanced AI technologies to improve efficiency and address unmet medical needs. The company’s mission centers on advancing state-of-the-art AI tools to design novel therapeutics across diverse disease areas, with a focus on oncology and immunology. By innovating in model architecture and developing cutting-edge capabilities, Isomorphic Labs seeks to enhance the drug discovery process and accelerate the delivery of new treatments.
The company’s unified AI drug design engine represents a significant advancement in the field, enabling the exploration of complex biological systems and the identification of potential therapeutic targets. This approach is designed to reduce the time and cost associated with traditional drug development while increasing the likelihood of successful outcomes. Isomorphic Labs’ collaborations with leading pharmaceutical companies further underscore its commitment to advancing AI-driven solutions in drug discovery.
Through its ambitious portfolio of internal programs and partnerships, Isomorphic Labs is positioned to make meaningful contributions to AI drug discovery. The company’s focus on continuous innovation and interdisciplinary collaboration reflects its vision to redefine how drugs are designed and developed, ultimately benefiting patients worldwide.
Collaborations with Pharmaceutical Leaders
Isomorphic Labs has established collaborations with leading pharmaceutical companies, including Eli Lilly and Novartis, to advance its AI-driven drug discovery efforts. These partnerships aim to leverage the company’s unified AI drug design engine to explore novel therapeutic targets across multiple disease areas. By combining Isomorphic Labs’ advanced computational capabilities with the pharma leaders’ expertise in clinical development, these collaborations seek to accelerate the identification of promising drug candidates.
Through these collaborations, Isomorphic Labs is positioned to make meaningful contributions to the field of AI-driven drug discovery. Working alongside established pharmaceutical leaders, the company aims to bring innovative therapies to patients more quickly and effectively.
Leadership and Team Expansion
The recent funding round has enabled Isomorphic Labs to expand its leadership team and recruit top computational biology and data science talent. This expansion ensures a robust pipeline of expertise, allowing the company to manage growth effectively while maintaining focus on its mission to revolutionize therapeutic development through advanced AI technologies.
The experienced leadership team is now better equipped to navigate complex scientific challenges and drive innovation in AI-driven drug discovery.
More information
External Link: Click Here For More
